Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:BRNS NASDAQ:INMB NASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.63-3.0%$1.65$1.03▼$2.41$50.85M-0.3392,228 shs102,753 shsBRNSBarinthus Biotherapeutics$1.10-2.7%$1.29$0.64▼$2.92$46.01M-0.7529,800 shs162,293 shsINMBINmune Bio$2.01+2.0%$2.35$1.71▼$11.64$52.37M1.03759,153 shs472,641 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-2.98%+3.16%+1.87%+9.40%-16.41%BRNSBarinthus Biotherapeutics-6.30%-11.29%-10.57%+21.78%-10.57%INMBINmune Bio+2.03%+3.08%-21.48%-73.90%-67.74%ME23andMe0.00%0.00%0.00%0.00%-91.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.63-3.0%$1.65$1.03▼$2.41$50.85M-0.3392,228 shs102,753 shsBRNSBarinthus Biotherapeutics$1.10-2.7%$1.29$0.64▼$2.92$46.01M-0.7529,800 shs162,293 shsINMBINmune Bio$2.01+2.0%$2.35$1.71▼$11.64$52.37M1.03759,153 shs472,641 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-2.98%+3.16%+1.87%+9.40%-16.41%BRNSBarinthus Biotherapeutics-6.30%-11.29%-10.57%+21.78%-10.57%INMBINmune Bio+2.03%+3.08%-21.48%-73.90%-67.74%ME23andMe0.00%0.00%0.00%0.00%-91.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50176.07% UpsideBRNSBarinthus Biotherapeutics 3.00Buy$3.00172.73% UpsideINMBINmune Bio 2.57Moderate Buy$18.40815.42% UpsideME23andMe 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ME, INMB, BRNS, and ATNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold6/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ABRNSBarinthus Biotherapeutics$14.97M2.99N/AN/A$3.23 per share0.34INMBINmune Bio$50K1,068.72N/AN/A$1.45 per share1.39ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/ABRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)INMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME, INMB, BRNS, and ATNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/A8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25BRNSBarinthus BiotherapeuticsN/A7.897.89INMBINmune BioN/A4.204.20ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%BRNSBarinthus Biotherapeutics25.20%INMBINmune Bio12.72%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%BRNSBarinthus Biotherapeutics10.70%INMBINmune Bio35.70%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableBRNSBarinthus Biotherapeutics10740.72 million36.36 millionN/AINMBINmune Bio1026.59 million17.09 millionOptionableME23andMe77026.83 million19.77 millionNot OptionableME, INMB, BRNS, and ATNM HeadlinesRecent News About These Companies23andMe Offers $3.25 Million Deal for Canadian Data Breach ClassSeptember 12 at 5:30 PM | news.bloomberglaw.comN23andMe Seeks Court Approval of $50 Million Data Breach DealSeptember 6, 2025 | news.bloomberglaw.comNThese scientists found Alzheimer's in their genes. Here's what they did nextSeptember 3, 2025 | npr.orgNWhat causes stuttering? It might be in your DNASeptember 3, 2025 | npr.orgNThese scientists found Alzheimer’s in their genes. Here’s what they did nextSeptember 2, 2025 | thepublicsradio.orgTJaylen Brown: "I did my history — my 23andMe. TheyAugust 25, 2025 | msn.comWayne State study says stuttering isn’t your nerves, it’s your genesAugust 24, 2025 | 953mnc.com923andMe Board Approves Changes to CEO’s CompensationAugust 22, 2025 | tipranks.comWhy Ancestry Is the Best DNA Test Kit in 2025August 21, 2025 | cnet.com23andMe Holding Finalizes Asset Sales Amid BankruptcyAugust 19, 2025 | msn.comThe Family Fallout of DNA SurprisesAugust 18, 2025 | newyorker.comNA 1974 murder rocked a small Pittsburgh suburb. Police just found the woman’s killer using a 23andMe-like clueAugust 17, 2025 | yahoo.com23andMe Rebrands to Chrome Holding Co.August 15, 2025 | tipranks.comThey’ve Got Next: The 40 Under 40 - Evan Hill of Cravath, Swaine & MooreAugust 13, 2025 | news.bloomberglaw.comN'I took a DNA test and discovered devastating truth my family hid for 24 years'August 10, 2025 | mirror.co.ukMGenetics of Stuttering: Why It is More Than a Speech DisorderAugust 9, 2025 | msn.comWoman claims 23andMe test proves she’s the daughter of influential sculptor Fred EversleyAugust 9, 2025 | msn.comClaire's files second bankruptcy petition in 7 yearsAugust 6, 2025 | msn.com‘Protect your genetic data’: Court approves sale of 23andMe assets, including genetic samplesJuly 31, 2025 | msn.comUtah AG issues consumer advisory for 23andMe customersJuly 31, 2025 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025ME, INMB, BRNS, and ATNM Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.63 -0.05 (-2.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.66 +0.03 (+1.78%) As of 09/12/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Barinthus Biotherapeutics NASDAQ:BRNS$1.10 -0.03 (-2.65%) Closing price 09/12/2025 03:50 PM EasternExtended Trading$1.10 0.00 (-0.36%) As of 09/12/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.INmune Bio NASDAQ:INMB$2.01 +0.04 (+2.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.01 0.00 (0.00%) As of 09/12/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
